Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB

FRIDAY, Sept. 16, 2022 (HealthDay News) -- For patients with extensively drug-resistant (XDR) tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks, according to a study published in the Sept. 1 issue of the New England Journal of Medicine.
Francesca Conradie, M.B., B.Ch., from the University of the Witwatersrand in Johannesburg, South Africa, and colleagues enrolled participants with XDR tuberculosis, pre-XDR tuberculosis, or rifampicin-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued due to side effects. Participants were randomly assigned to receive bedaquiline for 26 weeks, pretomanid, and daily linezolid at a dose of 1,200 mg for 26 weeks or nine weeks or 600 mg for 26 weeks or nine weeks. One hundred eighty-one participants were enrolled.
The researchers found a favorable outcome for 93, 89, 91, and 84 percent of those receiving bedaquiline-pretomanid-linezolid with linezolid at a dose of 1,200 mg for 26 weeks or nine weeks or 600 mg for 26 weeks or nine weeks, respectively; peripheral neuropathy occurred in 38, 24, 24, and 13 percent, respectively; and myelosuppression occurred in 22, 15, 2, and 7 percent, respectively. In 51, 30, 13, and 13 percent of participants, the linezolid dose was modified (i.e., interrupted, reduced, or discontinued). In four participants (9 percent) who had received linezolid at a dose of 1,200 mg for 26 weeks, optic neuropathy developed.
"A 600-mg, 26-week regimen of linezolid appeared to have the most favorable risk-benefit profile among the regimens studied," the authors write.
Editorial (subscription or payment may be required)
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Related Posts
La ciencia revela un posible ‘aumento de consciencia’ justo antes de la muerte
MARTES, 2 de mayo de 2023 (HealthDay News) -- Las experiencias cercanas a la...
FDA Limits Use of J&J COVID Vaccine Due to Blood Clot Risk
THURSDAY, May 5, 2022 (HealthDay News) -- Citing the accumulated data on a...
Could Weight-Loss Surgery in Teens Raise Risks for Alcohol Abuse?
FRIDAY, Jan. 6, 2023 (HealthDay News) -- For teens who are obese, weight-loss...
Good Oral Health Linked to Improved Survival in Head & Neck Cancer
FRIDAY, Sept. 22, 2023 (HealthDay News) -- For patients with head and neck...
